References
- 이건세, Brouwer WBF, 이상일, 구혜원. 보건의료 경제성평가 방법론 고찰-연구설계와 비용추정을 중심으로. 보건행정학회지 2004; 14(2):58-77
- 이의경, 배은영, 이태진, 최용준, 박은자, 김동숙. 보험의약품의 급여관리제도 개선방안. 한국보건사회연구원.보건복지부 2003
- 최용준, 이태진, 이의경, 김윤. 우리나라 의약품 비용효과분석 연구의 현황. 보건경제연구 2003; 9(1): 59-78
- Anis AH and Gagnon Y. Using Economic Evaluations to Make Formulary Coverage Decisions. So much for Guidelines. Pharmacoeconomics. 2000 Jul; 18(1): 55-62 https://doi.org/10.2165/00019053-200018010-00006
- Baladi JF, MenonD, Otten N. Use of Economic Evaluation Guidelines: 2 years' Experience in Canada. Health Econonomics. 1998; 7:221-227 https://doi.org/10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO;2-N
- Briggs A and Fenn P. Trying to do Better than Average: A coomentary on 'Statstical Inference for CostEffectiveness Ratios'. Health Economics 1997; 6:491-495 https://doi.org/10.1002/(SICI)1099-1050(199709)6:5<491::AID-HEC293>3.0.CO;2-R
- Canadian Coordinating Office for Health Technology Assessment, Guidelines for Authors of CCOHTA Health Technology Assessment Reports, June 2001 Revised May 2003. Available from URL: https://www.ccohta.ca/entry_e.html
- Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and Validation of a Grading System for the Quality of Cost-effectiveness Studies. Medical Care 2003; 41(1):32-44 https://doi.org/10.1097/00005650-200301000-00007
- Drummond M and McGuire A. Economic Evaluation in Health Care: Merging theory with practice. Oxford University Press; 2001. pp. 256-276
- Drummond MF and Jefferson TO. Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ. BMJ 1911; 313:275-283
-
Drummond MF, O'Brien B, Stoddart GL, and Torrance GW. Methods for the Economic Evaluation of Health Care Programmes,
$2^{nd}$ Ed. Oxford Medical Publications; 1997. pp. 39-41 - Drummond MF. A Reappraisal of Economic Evaluation of Pharmaceuticals: Science or Marketing? Pharmacoeconomics 1998 Jul; 14(1); 1-9
- Drummond MF. The Use of Health Economic Information by Reimbursement Authorities. Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii60-3 https://doi.org/10.1093/oxfordjournals.rheumatology.a005753
-
Enstrom A, Jacob J, Lundin D, Odeberg S, Ramsberg J. Examinging the Quality of Health Economic Analyses Submitted to the Pharmaceutical Benefits Board in Sweden. ISPOR
$10^{th}$ Annual Meeting Poster Presentation. 2005 - George B, Harris A, Mitchell A Costeffectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19(11):1103-9 https://doi.org/10.2165/00019053-200119110-00004
- Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press 1996
- Helmgren J. Berggren F, Anderson F. Health Economic Guidelines -Similarities, Differences and Some Implications. Value in Health 2001; 4(3); 224-250
- Hill SR, Mitchell AS, Herny DA. Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000 April; 283(16); 2116-2121 https://doi.org/10.1001/jama.283.16.2116
- National Institute for Clinical Excellence. Guide to the Method of Technology Appraisal. April 2004. Available from URL: http://www.nice.org.uk/page.aspx?o=201971
- Ofman JJ, Sullivan SD, Neuman PJ, Choiu CF, Hennig JM, Wade SW, Hay JW. Examining the Value and Quality of Health Economic Analysis: Implications of Utilizing the QHES, JMCP. 2003;9(1): 53-61
- Sculpher M, Fenwick E, Claxton K, Assessing Quality in Decision Analytic Cost-Effectiveness Models. Pharmacoeconomics 2000 May; 17(5); 461-477 https://doi.org/10.2165/00019053-200017050-00005
- Tarn TYH, Smith MD, Pharmacoeconomic Guidelines Around the World, ISPOR newsletter CONNECTIONS 2004; 10(4)
- Welte R, Feenstra T, Jager H and Leid R, A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries, Pharmacoeconomics 2004; 22(13): 857-876 https://doi.org/10.2165/00019053-200422130-00004
- http:;/www.ispor.org/PEguidelines/index.asp
Cited by
- Current State and Challenges of Pharmacoeconomic Evaluation in Korea vol.41, pp.2, 2008, https://doi.org/10.3961/jpmph.2008.41.2.74